Weiss Multi-Strategy Advisers’s Pacira BioSciences PCRX Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-8,000	Closed	-$258K	–	605
2016 Q4	$258K	Sell	8,000 -900	-10%	-$30K	0.01%	371
2016 Q3	$305K	Buy	+8,900	New	+$349K	0.02%	376
2015 Q4	–	Sell	-27,500	Closed	-$1.13M	–	439
2015 Q3	$1.13M	Buy	+27,500	New	+$1.68M	0.05%	250
2015 Q2	–	Sell	-14,000	Closed	-$1.24M	–	511
2015 Q1	$1.24M	Sell	14,000 -2,000	-13%	-$203K	0.06%	301
2014 Q4	$1.42M	Buy	16,000 +4,000	+33%	+$378K	0.05%	247
2014 Q3	$1.16M	Sell	12,000 -3,000	-20%	-$292K	0.03%	360
2014 Q2	$1.38M	Buy	15,000 +5,000	+50%	+$381K	0.03%	378
2014 Q1	$700K	Buy	+10,000	New	+$680K	0.01%	562

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Westfield Capital Management

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Alyeska Investment Group

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return